Drugmakers — including Pfizer Inc, Sanofi SA and GlaxoSmithKline PLC (GSK) — plan to raise prices on more than 300 drugs in the US from yesterday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.
The increases come as drugmakers are reeling from effects of the COVID-19 pandemic, which has reduced doctor visits and demand for some drugs. They are also fighting new drug price cutting rules from US President Donald Trump’s administration, which would reduce the industry’s profitability.
The companies kept their price increases at 10 percent or below, and the largest drug companies to raise prices so far, Pfizer and Sanofi, kept nearly all of their increases at 5 percent or less, said 3 Axis, a consulting firm that works with pharmacists groups, health plans and foundations on drug pricing and supply chain issues.
Photo: EPA-EFE
GSK did raise prices on two vaccines — shingles vaccine Shingrix, and diphtheria, tetanus and pertussis vaccine Pediarix — by 7 percent and 8.6 percent, respectively, 3 Axis said.
Teva Pharmaceuticals Inc hiked prices on 15 drugs, including Austedo, which treats rare neurological disorders, and asthma steroid Qvar, which together grossed more than US$650 million in sales in 2019 and saw price hikes of 5 to 6 percent.
Teva hiked prices for some drugs — including muscle relaxant Amrix and narcolepsy treatment Nuvigil — by as much as 9.4 percent.
More price hikes were expected to be announced yesterday, as well as early this month.
Last year, drugmakers raised prices on more than 860 drugs by an average of about 5 percent, 3 Axis said.
Drug price increases have slowed substantially since 2015, in terms of amount and the number of drugs affected.
The increases come as pharmaceutical companies such as Pfizer are playing hero by developing vaccines for COVID-19 in record time.
The hikes could help make up for lost revenue, as doctors’ visits and new prescriptions plummeted during COVID-19 lockdowns.
Pfizer plans to raise prices on more than 60 drugs by 0.5 to 5 percent, including increases of about 5 percent on some top sellers, such as rheumatoid arthritis treatment Xeljanz, and cancer drugs Ibrance and Inlyta.
Pfizer said that it adjusted the list prices of its drugs by about 1.3 percent across all products in its portfolio, in line with inflation.
“This modest increase is necessary to support investments that allow us to continue to discover new medicines and deliver those breakthroughs to the patients who need them,” spokeswoman Amy Rose said in a statement, pointing in particular to the COVID-19 vaccine that the company developed with Germany’s BioNTech SE.
Pfizer’s net prices have actually fallen for the past three years, it said.
France’s Sanofi plans to increase prices on a number of vaccines by 5 percent or less, and would announce more price increases later this month, spokeswoman Ashleigh Koss said.
None of the company’s price increases would be above 5.1 percent, the expected growth rate of US health spending, she said.
Slashing US prescription drug prices — which are among the highest in the world — was a focus of Trump, after making it a core pledge of his 2016 campaign.
Late last year, Trump issued several executive orders meant to cut prices, but their effect could be limited by legal challenges and other problems.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last